In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.

Journal Compilation © 2012 Acta Dermato-Venereologica. ISSN 0001-5555 Proton pump inhibitors and H2-receptor antagonists are widely used in the treatment of peptic ulcers and gastric acid-related diseases, because of their acid production inhibitory properties. Another group of frequently prescribed drugs, statins are used to significantly decrease the serum levels of cholesterol, thus stabilizing atherosclerotic plaques. Statins, as well as proton pump inhibitors and H2-receptor antagonists, are generally well tolerated. However, there are some case reports of photosensitive side-effects (1–12): ranitidine has been shown to induce increased photosensitivity, whereas pantoprazole, lansoprazole and omeprazole have been associated with the development of cutaneous lupus erythematosus, a known photosensitive skin disease. Furthermore, statins mainly induced chronic actinic dermatitis. We therefore assessed the in vitro phototoxic potential of several proton pump inhibitors, H2 antagonists, and statins, using a photohaemolysis test. This assay is an established in vitro method used in isolated erythrocytes for measurement of possible phototoxic effects. The effects of anti-oxidative substances (e.g. ascorbic acid, Trolox®, a water-soluble derivative of vitamin E) can also be assessed easily.

[1]  J. Toribio,et al.  Erythema multiforme photoinduced by statins , 2010, Photodermatology, photoimmunology & photomedicine.

[2]  S. Meehan,et al.  Lichenoid drug eruption. , 2009, Dermatology online journal.

[3]  E. Martínez-Barba,et al.  Cutaneous hyperpigmentation induced by omeprazole mimicking ashy dermatosis , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  R. Scolyer,et al.  Pravastatin‐induced lichenoid drug eruption , 2006, The Australasian journal of dermatology.

[5]  S. Onoue,et al.  Analytical Studies on the Prediction of Photosensitive/Phototoxic Potential of Pharmaceutical Substances , 2006, Pharmaceutical Research.

[6]  T. Nijsten,et al.  Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. , 2005, Acta dermato-venereologica.

[7]  A. Anstey,et al.  Chronic actinic dermatitis secondary to simvastatin , 2002, Photodermatology, photoimmunology & photomedicine.

[8]  J. Polónia,et al.  Possible phototoxicity with subsequent progression to discoid lupus following pantoprazole administration , 2001, Clinical and experimental dermatology.

[9]  K. Jimbow,et al.  UVB Photosensitivity due to Ranitidine , 2000, Dermatology.

[10]  C. Torre,et al.  Chronic actinic dermatitis due to simvastatin , 1998, Contact dermatitis.

[11]  B. Eberlein-König,et al.  Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and d-alpha-tocopherol (vitamin E). , 1998, Journal of the American Academy of Dermatology.

[12]  B. Eberlein-König,et al.  Phototoxic lysis of erythrocytes from humans is reduced after oral intake of ascorbic acid and d‐α‐tocopherol , 1997, Photodermatology, photoimmunology & photomedicine.

[13]  C. Proby,et al.  Likely photosensitizing agents available in the United Kingdom—an update , 1996, Clinical and experimental dermatology.

[14]  A. Kawada,et al.  Photosensitivity to simvastatin with an unusual response to photopatch and photo tests , 1995, Contact dermatitis.

[15]  J. Ring,et al.  Demonstration of quinolone phototoxicity in vitro. , 1990, Dermatologica.

[16]  M. Takahashi,et al.  Oxidative hemolysis of erythrocytes and its inhibition by free radical scavengers. , 1988, The Journal of biological chemistry.

[17]  I. Gigli,et al.  Delayed phase of hematoporphyrin-induced phototoxicity: modulation by complement, leukocytes, and antihistamines. , 1985, The Journal of investigative dermatology.